TIL

Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials

Obsidian Therapeutics aims to show its TIL cell therapy has advantages over an Iovance Biotherapeutics TIL therapy marketed for treating melanoma. Obsidian’s merger with Galera Therapeutics will give it a public listing and a private placement to support clinical development of the combined company’s cancer drug pipeline.

By Frank Vinluan

BioPharma, Pharma

Market forecasts see easy road ahead for cell therapies in oncology

One report forecasts $25 billion in global sales in six years, but cell therapies to date have been slow to catch on.

By Alaric DeArment

The Healthcare Payments Industry Has a Perception Problem

Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.

By Lisa Brooks, Vice President, Healthcare Partnerships

The Power of Real World Data to Study Women’s Health at Scale

Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!

By Veradigm and MedCity News

Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials

Market forecasts see easy road ahead for cell therapies in oncology

Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork